Clinical Trial Update: MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO) [Phase 3]

View source ↗

Summary

Phase 3 trial MATAO is evaluating maintenance therapy with an aromatase inhibitor in epithelial ovarian cancers; the study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• High-grade Serous Ovarian Carcinoma
• Low-grade Serous Ovarian Carcinoma
• Ovarian Cancer
• Ovarian Endometrioid Carcinoma
• Peritoneal Cancer

Drugs mentioned

• Aromatase inhibitor (unspecified) (aromatase inhibitor)

Snippet

Sponsor: Swiss GO Trial Group | Conditions: Ovarian Neoplasm Epithelial, Fallopian Tube Neoplasms | Phase 3 | Status: RECRUITING